AUTOPHAGY MODULATORS FOR TREATING NEURODEGENERATIVE DISEASES

SUMMARY

Small molecules that increase autophagy in human cells have been identified. The compounds decrease the amount of protein aggregate in cells and have been shown to selectively reduce the amount of mutant huntingtin protein in human cells.

REFERENCE NUMBER

E-223-2015

PRODUCT TYPE

- Therapeutics

KEYWORDS

- Huntington's Disease; Autophagy; Neurodegenerative diseases

COLLABORATION OPPORTUNITY

This invention is available for licensing and co-development.

CONTACT

Martha Lubet
NICHD - Eunice Kennedy Shriver National Institute on Child Health and Human Development
240-276-5508

Martha.Lubet@nih.gov

DESCRIPTION OF TECHNOLOGY

Small molecules that increase autophagy in human cells have been identified. The compounds decrease the amount of protein aggregate in cells and have been shown to selectively reduce the amount of mutant huntingtin protein in human cells.

POTENTIAL COMMERCIAL APPLICATIONS

- Treatment of Huntington's disease and other diseases characterized by accumulation of mutant proteins.

COMPETITIVE ADVANTAGES

- Agents that increase autophagy are a novel approach to treating diseases characterized by accumulation of mutant proteins.

INVENTOR(S)

Melvin DePamphilis (NICHD) and Lori Griner (NICHD)

Dr. DePamphilis's website: http://depamphilislab.nichd.nih.gov/index.html

DEVELOPMENT STAGE

- Discovery (Lead Identification)

PUBLICATIONS

In preparation

PATENT STATUS

- **Foreign Filed:** PCT application, PCT/US1635830, Filed June 3, 2016

THERAPEUTIC AREA

- Central Nervous System, Mental and Behavioral, Pain